Ravaud A - Search Results

1

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

Vano YA, Ladoire S, Elaidi R, Dermeche S, Eymard JC, Falkowski S, Gross-Goupil M, Malouf G, Narciso B, Sajous C, Tartas S, Voog E, Ravaud A. Vano YA, et al. Among authors: ravaud a. Cancers (Basel). 2021 Nov 5;13(21):5548. doi: 10.3390/cancers13215548. Cancers (Basel). 2021. PMID: 34771710 Free PMC article. Review.

2

Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.

Ravaud A, Grossgoupil M. Ravaud A, et al. Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7. Lancet Oncol. 2010. PMID: 20359658 No abstract available.

3

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.

Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H, Ravaud A. Roca S, et al. Among authors: ravaud a. Acta Oncol. 2011 Oct;50(7):1135-6. doi: 10.3109/0284186X.2011.592149. Epub 2011 Jul 5. Acta Oncol. 2011. PMID: 21726178 No abstract available.

4

Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Gross-Goupil M, Massard C, Ravaud A. Gross-Goupil M, et al. Among authors: ravaud a. Curr Urol Rep. 2012 Feb;13(1):16-23. doi: 10.1007/s11934-011-0232-y. Curr Urol Rep. 2012. PMID: 22139625 Review.

5

Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma.

Ravaud A, Gross-Goupil M. Ravaud A, et al. Cancer Treat Rev. 2012 Dec;38(8):996-1003. doi: 10.1016/j.ctrv.2012.01.003. Epub 2012 Feb 12. Cancer Treat Rev. 2012. PMID: 22330762 Review.

6

[Strategy in advanced castration-resistant prostate cancer].

Gross-Goupil M, Roca S, Pasticier G, Ravaud A. Gross-Goupil M, et al. Among authors: ravaud a. Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562. Bull Cancer. 2012. PMID: 22522582 Review. French.

7

Lapatinib and renal cell carcinoma.

Gross-Goupil M, Bernhard JC, Ravaud A. Gross-Goupil M, et al. Among authors: ravaud a. Expert Opin Investig Drugs. 2012 Nov;21(11):1727-32. doi: 10.1517/13543784.2012.713935. Epub 2012 Aug 9. Expert Opin Investig Drugs. 2012. PMID: 22876762 Review.

8

Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.

Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Daste A, et al. Among authors: ravaud a. Target Oncol. 2014 Mar;9(1):81-4. doi: 10.1007/s11523-012-0245-6. Epub 2013 Jan 3. Target Oncol. 2014. PMID: 23283668 Review.

9

Optimal management of renal cell carcinoma in the elderly: a review.

Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A. Quivy A, et al. Among authors: ravaud a. Clin Interv Aging. 2013;8:433-42. doi: 10.2147/CIA.S30765. Epub 2013 Apr 19. Clin Interv Aging. 2013. PMID: 23626463 Free PMC article. Review.

10

Combination therapy in metastatic renal cell cancer.

Ravaud A, Gross-Goupil M, Bellmunt J. Ravaud A, et al. Semin Oncol. 2013 Aug;40(4):472-81. doi: 10.1053/j.seminoncol.2013.05.010. Semin Oncol. 2013. PMID: 23972711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page